Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023
February 20, 2023 07:00 ET
|
Oxford BioMedica plc
Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023 Dr Mathias brings a wealth of experience in innovation, contract development and manufacturing to Oxford BiomedicaStuart...
Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer
November 22, 2022 07:00 ET
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...
Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million
November 14, 2022 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million Oxford, UK – 14 November 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a...
Amendment of Short-Term Loan Facility into new Term Loan Facility With Oaktree
October 07, 2022 07:00 ET
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...
OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022
September 15, 2022 07:00 ET
|
Oxford BioMedica plc
OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2022 SIGNIFICANT STRATEGIC AND OPERATIONAL PROGRESS TOWARDS BECOMING A GLOBAL VIRAL VECTOR LEADER Oxford, UK – 15 September 2022:...
Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy
July 26, 2022 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica Signs Licence & Supply Agreement with New Partner for LentiVector® Platform for CAR-T Therapy Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or...
Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology
July 26, 2022 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica initiates new project with Orchard Therapeutics utilising LentiStable™ technology Oxford, UK – 26 July 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a...
Oxford Biomedica Preliminary Results
April 20, 2022 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica plcPreliminary results for the year ended 31 December 2021 Saving Lives Oxford, UK – 20 April 2022: Oxford Biomedica plc (LSE: OXB), (“Oxford Biomedica” or “the Group”), a leading...
Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solutions, a full scope AAV business in Boston, following closing of its deal with Homology
March 11, 2022 07:00 ET
|
Oxford BioMedica plc
Unique platform offering capabilities from vector design and process development through to clinical trials is now available to new customers Oxford, UK – 11 March 2022: Oxford Biomedica plc...
Oxford Biomedica announces update to agreement with Sio Gene Therapies
January 31, 2022 16:13 ET
|
Oxford BioMedica plc
Oxford Biomedica announces that Sio Gene Therapies intends to cease the license agreement for gene therapy programme in Parkinson’s disease Negligible financial impact on Oxford Biomedica in the...